Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6116217 | 0.94 | BTK (0.57) | BTKTNK2PIK3CDNUDT14PIK3CA | |
| SCHEMBL6116297 | 0.80 | BTK (0.80) | BTKTNK2 | |
| SCHEMBL6115994 | 0.79 | BTK (0.56) | BTK | |
| SCHEMBL6115611 | 0.77 | BTK (0.78) | BTK | |
| SCHEMBL6116208 | 0.77 | BTK (0.64) | BTKTNK2PIK3CDNUDT14PIK3CA | |
| SCHEMBL6116353 | 0.74 | BTK (0.60) | BTKPIK3CDNUDT14PIK3CAPIK3CB | |
| SCHEMBL6116076 | 0.74 | BTK (0.68) | BTKPIK3CDNUDT14PIK3CAPIK3CB | |
| SCHEMBL8535461 | 0.74 | BTK (0.54) | BTKTNK2 | |
| SCHEMBL1162998 | 0.73 | BTK (0.69) | BTK | |
| SCHEMBL6116238 | 0.73 | BTK (0.77) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | claimed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | claimed |
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2789615-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | BTK 1/4885TNK2 154/4885IKBKE 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.